Inhaled Iloprost for patients with pulmonary arterial hypertension and right heart failure:a pilot feasibility trial

niv.Clinic of Internal Medicine II, Department of Cardiology, Medical University of Vienna, Austria0 个研究点目标入组 8 人开始时间: 2008年2月20日最近更新: 2013年4月8日

适应症

试验速览

暂无简介。

•a)PAH classification (according to Pulmonary Hypertension-Executive Summary 2003, Venice
•b)Echocardiographic and clinical signs of right heart failure, such as dyspnea, tachycardia, edema
•c)Mean right atrial pressure (mRAP) >15mmHg, cardiac index (CI) <2l/min/m2
•d)Written informed consent at the time of initial screening in conscious patients. In unconscious patients the treating physician will judge eligibility and the patients have to sign informed consent after regaining consciousness according to the Austrian regulations.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•a)Age younger than 18 years
•b)Right ventricular failure in the absence of PAH
•c)Pulmonary venous hypertension due to left-sided atrial, ventricular or valvular heart disease
•d)Known hypersensitivity to study drug or any ingredient
•e)Hypertrophic obstructive cardiomyopathy
•f)Significant aortic stenosis

发起方

niv.Clinic of Internal Medicine II, Department of Cardiology, Medical University of Vienna, Austria